Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRuE-V MOA: Ruxolitinib Cream Mechanism of Action in Vitiligo
NCT04896385Phase 2Completed
- Sponsor
- Incyte
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ruxolitinib cream in nonsegmental vitiligo (NSV), sponsored by Incyte. Started Jun 2021; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT04896385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896385.